FLUID-SCREEN, INC. | Application Preview
FLUID-SCREEN, INC. is seeking government grants to support various operational costs, including office and laboratory rentals, salaries, and research and development supplies. The company's business plan focuses on implementing batch processing in biomanufacturing, reducing the timeframe for next-generation CAR-T treatments, and licensing their technology across healthcare, food and beverage manufacturing, and water quality testing sectors.
The proposal emphasizes the soundness of investing in FLUID-SCREEN, highlighting established contracts with major pharmaceutical firms such as Pfizer, Takeda, and Johnson & Johnson. As a multi-patented entity nearing the final stages of start-up status, the company aims to revolutionize quality control processes with its innovative technology that enables real-time detection of bacterial contamination. This advancement helps eliminate the delays common in current testing methods, facilitating quicker and more responsive decisions regarding product and patient safety.
FLUID-SCREEN faces competition from firms like Biomerieux ScanRDI, Biomerieux BactAlert, and Rapid MicroBiosystems. However, its competitive advantage lies in the speed and efficiency of its testing technology, which produces results in minutes rather than days, significantly reducing potential losses for pharmaceutical companies caused by delays. Additionally, its technology does not require highly-trained personnel, unlike competitors, marking it as a significant breakthrough in the field.
-
General Information
Business Registration Number: FLUID-SCREEN, INC.
Location: BEVERLY, MA, United States
Length of Operation: 6-10
Number of Employees: 1-10 Employees
Annual Gross Income: $250k to $500k
Annual Gross Expense: $1M to $10M
Open to Loans: YES
-
Funding Usage
We will use it to pay office and laboratory rental fees, salary payments, R&D supplies and chips.
-
Business Plan
We are planning to implement batch processing in biomanufacturing, shortened period of enabling next-generation CAR-T, technology licensing for healthcare, food and beverage manufacturing, and water quality testing. You should invest in us as we have already established successful contracts with large pharmaceutical companies such as Pfizer, Takeda, Johnson & Johnson etc. We are a multi-patented company that is now very near to graduating as a start-up company. Our technology has the potential to help reimagine and support the next generation of quality control processes. With a wide range of applications such as biotherapeutics manufacturing, healthcare, and water quality monitoring industries, we aim to provide real-time detection and identification of bacterial contamination. By removing time delays associated with current methods, the Fluid-Screen platform allows for responsive, pro-active decision making when product, patient, and customer safety is at risk.
-
Self Identified Competition
1. Biomerieux ScanRDI 2. Biomerieux BactAlert 3. Rapid MicroBiosystems For l 30 years we have been growing bacteria on Petri dishes and waiting days for the test results. Delays in getting test results delay pharmaceutical production and cost pharmaceutical companies millions in product losses and recalls. Our technology generates results of bacterial testing in minutes, whereas our competitors do it in days. Secondly, our patented technology do not require highly-trained personnel, whereas our competitors do need it. This is indeed a breakthrough tehcnology.
-
Contact Applicant
Subscribe to our Administrator Dashboard to gain full access to this application. Learn More
